Sugi Predict

Sugi Predict / Compounds / SCHEMBL877447

SCHEMBL877447

SCHEMBL877447

O=S(=O)(O)c1c(O)ccc2[nH]c3ccccc3c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IMPDH2 P12268 1/20 0.54
▸ IMPDH1 P20839 1/20 0.54
▸ CDK4 P11802 2/20 0.46
▸ CCND1 P24385 2/20 0.46
▸ GABRP O00591 1/20 0.45
▸ GABRD O14764 1/20 0.45
▸ GABRA1 P14867 1/20 0.45
▸ GABRB1 P18505 1/20 0.45
▸ GABRG2 P18507 1/20 0.45
▸ GABRB3 P28472 1/20 0.45
▸ GABRA5 P31644 1/20 0.45
▸ GABRA3 P34903 1/20 0.45
▸ GABRA2 P47869 1/20 0.45
▸ GABRB2 P47870 1/20 0.45
▸ GABRA4 P48169 1/20 0.45
▸ GABRE P78334 1/20 0.45
▸ GABRA6 Q16445 1/20 0.45
▸ GABRG1 Q8N1C3 1/20 0.45
▸ GABRG3 Q99928 1/20 0.45
▸ GABRQ Q9UN88 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886902 0.85 IMPDH2 (0.47) IMPDH2IMPDH1CDK4CCND1GABRP
SCHEMBL3878246 0.75 IMPDH2 (0.66) IMPDH2IMPDH1CDK4CCND1GABRP
SCHEMBL30392623 0.75 IMPDH2 (0.66) IMPDH2IMPDH1CDK4CCND1GABRP
SCHEMBL633783 0.75 IMPDH2 (0.55) IMPDH2IMPDH1CDK4CCND1GABRP
SCHEMBL10651785 0.73 CHEK1 (0.46) IMPDH2IMPDH1CDK4CCND1GABRP
SCHEMBL10654323 0.73 PRKCA (0.45) IMPDH2IMPDH1CDK4CCND1GABRP
Carbazole SCHEMBL16345387 0.73 ALDH1A1 (0.64) IMPDH2IMPDH1GABRPGABRDGABRA1
SCHEMBL3878064 0.73 IMPDH2 (0.61) IMPDH2IMPDH1CDK4CCND1GABRP
Carbazole SCHEMBL10650068 0.72 ALDH1A1 (0.70) IMPDH2IMPDH1GABRPGABRDGABRA1
Carbazole SCHEMBL742559 0.72 ALDH1A1 (0.70) IMPDH2IMPDH1GABRPGABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11351274-B2 Methods of using optical agents MEDIBEACON INC. (US) 2022-06-07 — — US claimed
EP-1986701-B1 OPTICAL AGENTS FOR USE IN SURGERY MALLINCKRODT LLC (US) 2012-06-13 — — EP claimed
US-20240125703-A1 SYSTEMS AND METHODS FOR QUANTIFYING USER OBSERVED VISUALIZATION OF FLUORESCENCE IMAGING AGENTS STRYKER CORPORATION 2024-04-18 — — US disclosed
WO-2024059825-A1 SYSTEMS AND METHODS FOR QUANTIFYING USER OBSERVED VISUALIZATION OF FLUORESCENCE IMAGING AGENTS STRYKER CORPORATION (US) 2024-03-21 — — WO disclosed
WO-2023069892-A1 CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASES SHORT JAY M (US) 2023-04-27 — — WO disclosed
US-11607458-B2 Enrichment-triggered chemical delivery system GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2023-03-21 — — US disclosed
US-11351274-B2 Methods of using optical agents MEDIBEACON INC. (US) 2022-06-07 — — US disclosed
US-20220127595-A1 CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS BIOATLA, INC. (US) 2022-04-28 — — US disclosed
US-11254932-B2 Conditionally active biological proteins BIOATLA, INC. (US) 2022-02-22 — — US disclosed
US-11185597-B2 Process for using optical agents MEDIBEACON, INC. (US) 2021-11-30 — — US disclosed
US-11135309-B2 Poly(vinyl alcohol) nanocarriers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-05 — — US disclosed
US-6716413-B1 BENZOTHIAZOLE DERIVATIVES THAT ABSORB AND FLUORESCE IN VISIBLE LIGHT ARE USED FOR OPTICAL DIAGNOSIS OF KIDNEY AND CARDIOVASCULAR DISORDERS MALLINCKRODT, INC. 2004-04-06 — — US disclosed
EP-1326649-A1 TISSUE-SPECIFIC EXOGENOUS OPTICAL AGENTS MALLINCKRODT INC. (US) 2003-07-16 — — EP disclosed
EP-1326650-A2 HYDROPHILIC LIGHT ABSORBING COMPOSITIONS FOR DETERMINATION OF PHYSIOLOGICAL FUNCTION IN CRITICALLY ILL PATIENTS Mallinckrodt Inc. (US) 2003-07-16 — — EP disclosed
EP-1326648-A1 NOVEL DYES FOR ORGAN FUNCTION MONITORING Mallinckrodt Inc. (US) 2003-07-16 — — EP disclosed
EP-1326602-A1 INDOLE COMPOUNDS AS MINIMALLY PHYSIOLOGIAL FUNCTION MONITIORING AGENTS MALLINCKRODT INC. (US) 2003-07-16 — — EP disclosed
WO-2002032464-A1 NOVEL DYES FOR ORGAN FUNCTION MONITORING MALLINCKRODT INC. (US) 2002-04-25 — — WO disclosed
WO-2002032421-A1 INDOLE COMPOUNDS AS MINIMALLY PHYSIOLOGIAL FUNCTION MONITIORING AGENTS MALLINCKRODT INC. (US) 2002-04-25 — — WO disclosed
WO-2002032285-A2 HYDROPHILIC LIGHT ABSORBING COMPOSITIONS FOR DETERMINATION OF PHYSIOLOGICAL FUNCTION IN CRITICALLY ILL PATIENTS MALLINCKRODT INC. (US) 2002-04-25 — — WO disclosed
WO-2002032465-A1 TISSUE-SPECIFIC EXOGENOUS OPTICAL AGENTS MALLINCKRODT INC. (US) 2002-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11607458-B2 Enrichment-triggered chemical delivery system HMGB1, PAICS, CCL2 IMPDH2 3929/4885IMPDH1 4174/4885CDK4 278/4885
US-11135309-B2 Poly(vinyl alcohol) nanocarriers ADH1A, HCCS, ADH1C IMPDH2 3496/4885IMPDH1 3539/4885CDK4 1548/4885
US-11185597-B2 Process for using optical agents REN, ATP6V1B1, VHL IMPDH2 2565/4885IMPDH1 2391/4885CDK4 1786/4885
US-11351274-B2 Methods of using optical agents REN, ATP6V1B1, VHL IMPDH2 3057/4885IMPDH1 3046/4885CDK4 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.